World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 28 February 2019
Main ID:  EUCTR2011-005249-12-ES
Date of registration: 01/04/2014
Prospective Registration: Yes
Primary sponsor: Genzyme Corporation
Public title: A two year, randomized, placebo-controlled study to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide once daily in pediatric patients with relapsing forms of multiple sclerosis
Scientific title: A two year, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide administered orally once daily in pediatric patients with relapsing forms of multiple sclerosis - TERIKIDS
Date of first enrolment: 03/06/2014
Target sample size: 165
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005249-12
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: yes Other trial design description: Option to go in an open label teriflunomide arm for patients having a relapse after PK run-in phase If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2  
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries of recruitment
Australia Belgium Bulgaria Canada China Estonia France Greece
Ireland Israel Lebanon Lithuania Netherlands Poland Portugal Russian Federation
Slovenia Spain Turkey United Kingdom United States
Contacts
Name: Unidad Estudios Clínicos   
Address:  c/ Josep Pla nº2 08019 Barcelona Spain
Telephone: 93 485 94 00
Email: ES-unidadestudiosclinicos@sanofi.com
Affiliation:  sanofi-aventis, s.a.
Name: Unidad Estudios Clínicos   
Address:  c/ Josep Pla nº2 08019 Barcelona Spain
Telephone: 93 485 94 00
Email: ES-unidadestudiosclinicos@sanofi.com
Affiliation:  sanofi-aventis, s.a.
Key inclusion & exclusion criteria
Inclusion criteria:
- Patients with relapsing multiple sclerosis (MS) based on McDonald criteria of 2010 and International Pediatric Multiple Sclerosis Study Group (IPMSG) criteria for pediatric MS:
-at least one relapse in the 12 months preceding randomization, or
-at least 2 relapses in the 24 months preceding randomization.
- Equal or less than 17 years of age and equal or greater than 10 years of age at randomization.
- Signed informed consent/assent obtained from patient and patient's legal representative.
Are the trial subjects under 18? yes
Number of subjects for this age range: 165
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
- Expanded disability status scale (EDSS) score greater than 5.5 at screening or randomization visit.
- Relapse within 30 days prior to randomization.
- Treated with cladribine or mitoxantrone within 2 years preceding randomization.
- Treated with glatiramer acetate, interferons, natalizumab, introvenous immunoglobulins or other immunosuppressant or immunomodulatory agents such as cyclophosphamide, azathioprine, cyclosporine, methotrexate, mycophenolate, dimetthyl fumrate, fingolimod less than 3 months or five half-lives prior to randomization, whichever is greater.
- History of human immunodeficiency virus (HIV) infection.
- Contraindication for magnetic resonance imaging (MRI).
- Pregnant or breast-feeding females or those who plan to become pregnant during the study.
- Female patients of child-bearing potential not using highly effective contraceptives or (double barrier) contraceptive method.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Multiple Sclerosis
MedDRA version: 16.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Intervention(s)

Product Name: Teriflunomide
Product Code: HMR1726
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: TERIFLUNOMIDE
CAS Number: 108605-62-5
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 14-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use

Product Name: Teriflunomide
Product Code: HMR1726
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: TERIFLUNOMIDE
CAS Number: 108605-62-5
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 7-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use

Product Name: Teriflunomide
Product Code: HMR1726
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: TERIFLUNOMIDE
CAS Number: 108605-62-5
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 3.5-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use

Primary Outcome(s)

Secondary Objective: To assess the effect of teriflunomide in comparison to placebo on disease activity/progression measured by brain MRI and on cognitive function.
To evaluate the safety and tolerability of teriflunomide in comparison to placebo.
To evaluate the pharmacokinetics (PK) of teriflunomide.
Main Objective: To assess the effect of teriflunomide in comparison to placebo on disease activity measured by time to first clinical relapse after randomization in children and adolescents 10 to 17 years of age with relapsing forms of multiple sclerosis.
Primary end point(s): Time to first clinical relapse after randomization
Timepoint(s) of evaluation of this end point: Over 96 weeks
Secondary Outcome(s)

Secondary end point(s): 1 - Proportion of relapse free patients
2 - Number of of new/newly enlarged T2 lesions
3 - Number of T1 Gd-enhancing T1 lesions
4 - Change in volume of T2 lesions
5 - Change in volume of T1 hypointense lesions
6 - Number of new T1 hypointense lesions
7 - Change in brain atrophy
8 - Change in performance on symbol digit modalities test (SDMT) and Cognitive Battery Test
9 - Overview of safety including adverse events (AEs) based on AE reporting, physical examinations, vital signs, clinical laboratories, suspected neuropathy, electrocardiography (ECG), suspected infection
10 - Teriflunomide pharmacokinetics (PK) to allow the dose adjustment to the 14 mg adult equivalent dose for the rest of the
study

Timepoint(s) of evaluation of this end point: 1 and 9 : Over 96 weeks
2, 3, 4, 5, 6 and 7 : At randomization, at 24, 48 and 96 weeks
8 : At randomization, then every 24 weeks (SDMT only) and at 96 weeks
10 : A total of 3 PK samples (blood samples) will be collected during the beginning of study, i.e., the 4-week PK run-in period (weeks 2, 3 and 4); patients entering the open label teriflunomide arm will re-do PK run-in (3 blood samples)
Secondary ID(s)
EFC11759
2011-005249-12-EE
Source(s) of Monetary Support
Genzyme Corporation
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date:
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history